Pharsight

Drugs that contain Megestrol Acetate

1. Megace Es patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6592903 ENDO PHARMS INC Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
Sep, 2020

(3 years ago)

US9101540 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(a day from now)

US7101576 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(a day from now)

US9107827 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(a day from now)

US9101549 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(a day from now)

US9040088 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(a day from now)

Market Authorisation Date: 05 July, 2005

Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)

Dosage: SUSPENSION;ORAL

How can I launch a generic of MEGACE ES before it's drug patent expiration?
More Information on Dosage

MEGACE ES family patents

Family Patents